Tinengotinib exhibits activity in pretreated breast cancer
A study presented at the San Antonio Breast Cancer Symposium showed that the multikinase inhibitor Tinengotinib exhibited activity among heavily pretreated patients with hormone receptor-positive, HER2-negative breast cancer or those with triple-negative disease. The majority of patients in the study experienced treatment-related adverse events, but they were manageable. Efficacy results included objective responses and clinical…